

Leverett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	13	8.6	150.3	(80-257.1)	Female	0	1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.8	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	0	2.2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.7	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male				
Male	0	0.2	nc	(nc-nc)	Female	9	10.8	83.7	(38.2-158.9)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	1.4	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male				
Male	0	0.4	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Female				
Male	1	0.9	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	3	4.7	nc	(nc-nc)	Female	27	35.2	76.8	(50.6-111.7)
Female	3	3.8	nc	(nc-nc)	Female	31	27.7	111.8	(76-158.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lexington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	44.1	61.2	(40.3-89)	Male	35	27	129.6	(90.3-180.3)
Female	9	16.1	55.9	(25.5-106)	Female	27	20.6	130.9	(86.2-190.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	7.5	159.6	(82.4-278.9)	Male	9	7.8	116.1	(53-220.4)
Female	4	6.4	nc	(nc-nc)	Female	8	6.4	124.8	(53.8-246)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	1.4	nc	(nc-nc)	Male	24	23.9	100.3	(64.3-149.3)
Female	172	159.5	107.8	(92.3-125.2)	Female	23	20.2	113.7	(72-170.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	5.2	nc	(nc-nc)	Male	8	17.6	45.6	(19.6-89.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	48.6	80.2	(57-109.6)	Female	14	14.6	96.2	(52.5-161.4)
Female	37	50.7	73	(51.4-100.7)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	11.4	nc	(nc-nc)	Male	156	154.8	100.8	(85.6-117.9)
Female	4	3.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	2.6	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	21	21.8	96.3	(59.6-147.2)	Female	30	36.4	82.4	(55.6-117.7)
Female	6	12.9	46.4	(16.9-100.9)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	4	6.2	nc	(nc-nc)	Male	23	16.3	141.3	(89.6-212.1)
Female	0	1.9	nc	(nc-nc)	Female	16	12	133	(76-216.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	6	13	46.2	(16.9-100.6)	Male	44	78.9	55.8	(40.5-74.9)
Female	4	4.6	nc	(nc-nc)	Female	46	80.7	57	(41.7-76)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Leyden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	3.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	7	3.8	183.3	(73.5-377.8)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	10	12.4	80.4	(38.5-147.9)
Male	0	0.3	nc	(nc-nc)	Female	5	10.3	48.5	(15.6-113.1)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.6	nc	(nc-nc)					
Female	2	1.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lincoln

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	8.4	nc	(nc-nc)	Male	4	5.4	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	7	3.8	182.1	(73-375.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	1	1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.3	nc	(nc-nc)	Male	7	4.7	148	(59.3-305)
Female	35	29.2	119.8	(83.4-166.6)	Female	4	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	9.4	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
Female	5	7.9	62.9	(20.3-146.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	44	31	142	(103.2-190.7)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.4	nc	(nc-nc)	Female	4	6.8	nc	(nc-nc)
Female	2	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	1.2	nc	(nc-nc)	Male	5	3.2	155	(49.9-361.7)
Female	0	0.3	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	2.6	nc	(nc-nc)	Male	7	15.3	45.6	(18.3-94)
Female	0	0.8	nc	(nc-nc)	Female	10	13.6	73.5	(35.2-135.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Littleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	9.3	96.8	(44.2-183.8)	Male	8	6.2	128.4	(55.3-253.1)
Female	0	3.3	nc	(nc-nc)	Female	2	4.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
Female	26	37.4	69.6	(45.4-101.9)	Female	6	4.4	135.6	(49.5-295.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	2	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	10.9	92.2	(44.1-169.5)	Female	3	3.3	nc	(nc-nc)
Female	11	10.6	103.5	(51.6-185.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.1	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	Female	6	3.2	187.6	(68.5-408.4)
Female	0	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	35.6	112.2	(80.2-152.8)
Male	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.3	nc	(nc-nc)
Male	6	5.2	115.1	(42-250.6)	<u>Testis</u>				
Female	2	2.9	nc	(nc-nc)	Male	4	1.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.4	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	7	7.1	98.8	(39.6-203.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	3.7	nc	(nc-nc)	Female	12	8.4	142.2	(73.4-248.5)
Female	3	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	123	127.8	96.2	(80-114.8)
Male	1	3	nc	(nc-nc)	Female	104	125.2	83.1	(67.9-100.6)
Female	1	1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	17	105.9	(62.7-167.4)					
Female	11	17.1	64.2	(32-114.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	22.1	40.7	(18.6-77.3)	Male	17	13.5	125.9	(73.3-201.5)
Female	6	8.2	72.8	(26.6-158.4)	Female	14	10.4	134	(73.2-224.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	4	3.9	nc	(nc-nc)
Female	3	3.2	nc	(nc-nc)	Female	3	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	12	12	100.1	(51.7-174.9)
Female	93	79.5	116.9	(94.4-143.2)	Female	12	10.3	116.7	(60.2-203.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	5	8.9	56.3	(18.1-131.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	11	24.5	44.9	(22.4-80.3)	Female	6	7.4	81.5	(29.8-177.4)
Female	11	26.2	42	(20.9-75.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	7.2	nc	(nc-nc)
Male	6	5.7	104.5	(38.2-227.5)	Female	4	8	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	79	78.4	100.7	(79.7-125.5)
Male	1	1.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	5.1	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	3.3	nc	(nc-nc)
Male	12	10.9	109.9	(56.7-192.1)	<u>Testis</u>				
Female	6	6.5	92.7	(33.8-201.7)	Male	4	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	3.1	nc	(nc-nc)	Male	5	4.4	113.2	(36.5-264.1)
Female	1	0.9	nc	(nc-nc)	Female	6	13	46.2	(16.9-100.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	9	8.2	109.6	(50-208.1)	Female	10	18.2	55.1	(26.4-101.3)
Female	3	6.2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	224	283.5	79	(69-90.1)
Male	2	6.6	nc	(nc-nc)	Female	246	280	87.9	(77.2-99.6)
Female	4	2.3	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	39.3	53.4	(33.1-81.7)					
Female	31	40.2	77	(52.3-109.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lowell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	81	82	98.8	(78.5-122.8)	Male	35	57.9	60.5	(42.1-84.1)
Female	48	32.4	148.2	(109.3-196.5)	Female	27	50.7	53.3	(35.1-77.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	19.3	72.4	(39.6-121.5)	Male	18	15.2	118.2	(70-186.8)
Female	15	16.2	92.3	(51.6-152.3)	Female	18	13.1	137.9	(81.7-218)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.6	nc	(nc-nc)	Male	59	51.2	115.1	(87.6-148.5)
Female	286	353.3	80.9	(71.8-90.9)	Female	33	43.6	75.7	(52.1-106.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	14	121.7	(70.9-194.9)	Male	52	38.7	134.5	(100.5-176.4)
Female					Female	13	17.3	75.1	(40-128.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	109	96.5	112.9	(92.7-136.2)	Female	27	32.2	83.7	(55.2-121.9)
Female	106	103.8	102.2	(83.6-123.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	26	27.4	95	(62-139.1)
Male	21	22.8	92.2	(57.1-141)	Female	20	31.3	63.9	(39-98.7)
Female	4	6.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	260	319.2	81.5	(71.9-92)
Male	7	9.7	72.3	(29-148.9)	<u>Stomach</u>				
Female	4	7.7	nc	(nc-nc)	Male	21	20	104.8	(64.8-160.2)
<u>Kidney & Renal Pelvis</u>					Female	19	12.7	149.4	(89.9-233.4)
Male	48	47.8	100.4	(74-133.1)	<u>Testis</u>				
Female	41	28.3	145.1	(104.1-196.9)	Male	11	17.5	62.8	(31.3-112.4)
<u>Larynx</u>					<u>Thyroid</u>				
Male	22	12.6	174.7	(109.5-264.6)	Male	25	23.6	105.9	(68.5-156.4)
Female	8	4.1	196.3	(84.5-386.8)	Female	78	75.3	103.6	(81.9-129.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	34	35.1	96.7	(67-135.2)	Female	87	79.4	109.6	(87.8-135.2)
Female	47	27.8	169.3	(124.4-225.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1207	1165.8	103.5	(97.8-109.5)
Male	57	27.3	208.7	(158-270.4)	Female	1183	1222.4	96.8	(91.3-102.5)
Female	9	9.6	93.4	(42.6-177.2)					
<u>Lung and Bronchus</u>									
Male	192	150.9	127.2	(109.9-146.6)					
Female	170	166.6	102	(87.3-118.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Ludlow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	27	25.3	106.6	(70.2-155.1)	Male	14	16.7	83.8	(45.8-140.6)
Female	7	9.2	76.2	(30.5-157.1)	Female	16	12.5	127.9	(73.1-207.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.9	142.8	(57.2-294.2)	Male	2	4.6	nc	(nc-nc)
Female	7	3.8	181.8	(72.8-374.7)	Female	2	3.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.8	nc	(nc-nc)	Male	12	14.7	81.9	(42.3-143)
Female	83	93.8	88.5	(70.5-109.7)	Female	8	11.8	67.9	(29.2-133.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.2	nc	(nc-nc)	Male	8	11.1	72.3	(31.1-142.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	37	28.7	128.8	(90.7-177.5)	Female	8	8.5	93.6	(40.3-184.4)
Female	24	28.7	83.5	(53.5-124.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	8.4	119.7	(57.3-220.1)
Male	6	6.9	87.4	(31.9-190.1)	Female	10	8.9	112.6	(53.9-207)
Female	1	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	93	95.9	97	(78.3-118.8)
Male	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.5	nc	(nc-nc)	Male	7	6	116.2	(46.5-239.4)
<u>Kidney & Renal Pelvis</u>					Female	4	3.5	nc	(nc-nc)
Male	15	13.7	109.9	(61.5-181.2)	<u>Testis</u>				
Female	3	7.6	nc	(nc-nc)	Male	5	3.6	137	(44.2-319.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.8	nc	(nc-nc)	Male	2	6.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	8	16.7	48	(20.7-94.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	10	9.8	102.2	(48.9-187.9)	Female	17	21.5	79	(46-126.5)
Female	6	7	86	(31.4-187.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	317	343.4	92.3	(82.4-103.1)
Male	6	8	75.1	(27.4-163.5)	Female	268	325.8	82.2	(72.7-92.7)
Female	1	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	29	46.4	62.5	(41.9-89.8)					
Female	36	47.5	75.8	(53.1-105)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lunenburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	11.1	63	(25.3-129.9)	Male	7	7.6	92.6	(37.1-190.8)
Female	2	3.6	nc	(nc-nc)	Female	2	5.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.3	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	3	6.6	nc	(nc-nc)
Female	36	43.1	83.5	(58.5-115.6)	Female	5	4.9	102.1	(32.9-238.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	13	99.9	(53.1-170.8)	Female	3	3.8	nc	(nc-nc)
Female	12	11.4	105.5	(54.4-184.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	4	3.7	nc	(nc-nc)
Male	3	3.2	nc	(nc-nc)	Female	1	3.4	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	45	120	(90.2-156.6)
Male	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	3	0.7	nc	(nc-nc)	Male	3	2.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.4	nc	(nc-nc)
Male	3	6.4	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.3	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.8	nc	(nc-nc)	Male	1	2.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	8.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.4	nc	(nc-nc)	Female	13	10	130.2	(69.3-222.7)
Female	1	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	151	156.5	96.5	(81.7-113.2)
Male	2	3.8	nc	(nc-nc)	Female	115	141.2	81.5	(67.2-97.8)
Female	3	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	22	20.7	106.1	(66.5-160.7)					
Female	14	19.2	72.7	(39.7-122.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	65	80.6	80.6	(62.2-102.8)	Male	48	54.3	88.4	(65.2-117.2)
Female	26	30.4	85.4	(55.8-125.2)	Female	27	46.3	58.4	(38.5-84.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	17.5	97.3	(56.7-155.8)	Male	23	14.6	157	(99.5-235.6)
Female	16	14.8	108.4	(61.9-176)	Female	9	12.3	73.2	(33.4-139)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.5	nc	(nc-nc)	Male	52	48.2	107.9	(80.6-141.5)
Female	323	329.6	98	(87.6-109.3)	Female	43	40.6	105.9	(76.6-142.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	14	12.6	111.2	(60.8-186.6)	Male	53	35.8	148.2	(111-193.8)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	97	92.8	104.5	(84.8-127.5)	Female	28	30	93.2	(61.9-134.8)
Female	112	96.8	115.7	(95.3-139.2)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	26	21.7	119.7	(78.2-175.4)	Male	319	300.6	106.1	(94.8-118.4)
Female	10	6.2	161.9	(77.5-297.8)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	6	8.1	74.2	(27.1-161.5)	Male	11	14	78.3	(39-140.1)
Female	1	6.6	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	44	44.4	99.1	(72-133)	Female	82	74.8	109.6	(87.1-136)
Female	27	26.4	102.2	(67.3-148.7)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	19	11.9	159.4	(95.9-248.9)	Male	41	33.3	123.1	(88.3-167)
Female	4	3.8	nc	(nc-nc)	Female	34	25.5	133.4	(92.3-186.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	45	25.6	175.5	(128-234.9)	Male	193	146.4	131.8	(113.9-151.8)
Female	11	9	121.6	(60.6-217.6)	Female	176	157.4	111.8	(95.9-129.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Lynnfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	16.4	91.6	(51.2-151)	Male	19	10.2	186.1	(112-290.7)
Female	7	5.3	131	(52.5-269.9)	Female	9	7.3	124	(56.6-235.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	9	167	(93.4-275.5)
Female	60	56.2	106.7	(81.4-137.3)	Female	8	6.9	116.2	(50-229)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.9	nc	(nc-nc)	Male	3	6.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	22	18.1	121.5	(76.1-184)	Female	10	5.1	197.1	(94.4-362.5)
Female	23	16.7	137.4	(87.1-206.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	5.3	93.6	(30.2-218.4)
Male	2	4.3	nc	(nc-nc)	Female	6	5.2	116.4	(42.5-253.5)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	62	59.7	103.8	(79.6-133)
Male	1	1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	2	nc	(nc-nc)
Male	12	8.3	144.1	(74.4-251.7)	<u>Testis</u>				
Female	5	4.5	110.9	(35.7-258.9)	Male	3	1.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	2.4	nc	(nc-nc)	Male	3	3.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	18	9.6	188	(111.3-297.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	6.1	181.2	(90.3-324.3)	Female	13	13	99.9	(53.2-170.9)
Female	7	4.1	172.7	(69.2-355.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	218	213.5	102.1	(89-116.6)
Male	1	4.9	nc	(nc-nc)	Female	226	192	117.7	(102.9-134.1)
Female	2	1.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	23	29.7	77.3	(49-116)					
Female	27	27.8	97.1	(64-141.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Malden

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	38	54.9	69.2	(48.9-94.9)	Male	13	37.2	34.9	(18.6-59.7)
Female	31	21.3	145.6	(98.9-206.7)	Female	22	32.3	68.2	(42.7-103.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	11.5	61	(24.4-125.6)	Male	5	10	50	(16.1-116.7)
Female	7	9.9	71	(28.4-146.2)	Female	7	8.6	81.6	(32.7-168.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.7	nc	(nc-nc)	Male	34	32.7	104	(72-145.3)
Female	195	228.3	85.4	(73.8-98.3)	Female	18	28.3	63.7	(37.7-100.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	8.9	56.4	(18.2-131.6)	Male	22	24.3	90.4	(56.7-136.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	73	63.2	115.6	(90.6-145.3)	Female	17	20.8	81.7	(47.5-130.7)
Female	78	67.6	115.4	(91.2-144.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	23	18.2	126.6	(80.2-190)
Male	18	14.8	121.3	(71.9-191.7)	Female	15	20.6	72.9	(40.8-120.2)
Female	11	4.3	254.5	(126.9-455.4)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	140	205.9	68	(57.2-80.2)
Male	3	5.5	nc	(nc-nc)	<u>Stomach</u>				
Female	6	4.5	133.5	(48.8-290.6)	Male	19	13.2	144.1	(86.7-225)
<u>Kidney & Renal Pelvis</u>					Female	6	8.3	72.5	(26.5-157.7)
Male	33	30.3	109	(75-153.1)	<u>Testis</u>				
Female	18	18.3	98.4	(58.3-155.5)	Male	10	9.9	101.3	(48.5-186.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	10	8.1	122.8	(58.8-225.9)	Male	16	14.4	111.3	(63.6-180.8)
Female	6	2.7	224	(81.8-487.6)	Female	57	47	121.2	(91.8-157)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	21	22.1	95.1	(58.8-145.3)	Female	58	51.8	112	(85-144.7)
Female	18	17.3	104.3	(61.8-164.9)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	678	752.9	90.1	(83.4-97.1)
Male	23	17.4	132.2	(83.8-198.4)	Female	783	790.2	99.1	(92.3-106.3)
Female	6	6.3	95.7	(34.9-208.2)					
<u>Lung and Bronchus</u>									
Male	118	100.2	117.8	(97.5-141.1)					
Female	125	109.9	113.7	(94.7-135.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Manchester by the Sea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	7.4	nc	(nc-nc)	Male	14	4.7	298.3	(163-500.6)
Female	2	2.6	nc	(nc-nc)	Female	8	3.5	228.4	(98.3-450.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	2	1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
Female	35	27.6	126.8	(88.3-176.4)	Female	3	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	8.3	84.8	(34-174.8)	Female	2	2.5	nc	(nc-nc)
Female	6	7.9	75.9	(27.7-165.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.4	nc	(nc-nc)
Male	3	2	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	35	28.8	121.4	(84.6-168.9)
Male	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1	nc	(nc-nc)
Male	2	3.9	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.2	nc	(nc-nc)	Male	3	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	9	4.6	194.5	(88.7-369.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	2.7	nc	(nc-nc)	Female	6	6.5	91.7	(33.5-199.6)
Female	3	1.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	97	99.2	97.7	(79.3-119.2)
Male	0	2.3	nc	(nc-nc)	Female	107	93.2	114.9	(94.1-138.8)
Female	0	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	7	13.7	51.1	(20.5-105.4)					
Female	8	13.6	59	(25.4-116.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mansfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	15.5	109.4	(63.7-175.2)	Male	18	11.9	151.6	(89.8-239.6)
Female	2	5.4	nc	(nc-nc)	Female	18	10.3	174	(103.1-275.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.2	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	7	3.2	216.2	(86.6-445.4)	Female	1	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.5	nc	(nc-nc)	Male	13	10.5	123.5	(65.7-211.2)
Female	75	74.4	100.8	(79.3-126.3)	Female	4	8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.2	nc	(nc-nc)	Male	10	8.5	118	(56.5-217)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	19.8	136.6	(90-198.7)	Female	6	6.4	93.7	(34.2-204)
Female	27	18.4	146.4	(96.5-213)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	5.3	nc	(nc-nc)
Male	5	4.6	109.3	(35.2-255.1)	Female	10	5.2	192.4	(92.1-353.9)
Female	0	1.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	59	64.5	91.5	(69.7-118.1)
Male	0	2	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.5	nc	(nc-nc)	Male	6	4	150	(54.8-326.5)
<u>Kidney & Renal Pelvis</u>					Female	0	2.2	nc	(nc-nc)
Male	10	10.3	97.5	(46.7-179.3)	<u>Testis</u>				
Female	8	5.5	146.7	(63.1-289)	Male	4	3.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	2.6	nc	(nc-nc)	Male	13	5.3	245.7	(130.7-420.1)
Female	0	0.8	nc	(nc-nc)	Female	22	17.4	126.5	(79.2-191.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	7.1	112.9	(48.6-222.5)	Female	11	16.1	68.4	(34.1-122.4)
Female	7	5.2	135.9	(54.4-280)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	250	235.3	106.3	(93.5-120.3)
Male	6	5.8	103.5	(37.8-225.2)	Female	272	237.9	114.3	(101.1-128.7)
Female	2	1.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	25	28.9	86.4	(55.9-127.6)					
Female	44	28.8	152.7	(110.9-204.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marblehead

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	26.2	80.3	(49.7-122.7)	Male	34	16.7	203.1	(140.6-283.8)
Female	12	9.2	131	(67.6-228.9)	Female	23	12.9	178	(112.8-267.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.8	nc	(nc-nc)	Male	6	4.7	126.7	(46.3-275.8)
Female	6	4	151.5	(55.3-329.8)	Female	5	3.7	133.9	(43.2-312.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	16	14.6	109.3	(62.5-177.6)
Female	130	100.2	129.7	(108.4-154)	Female	14	12	116.8	(63.8-196)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.4	nc	(nc-nc)	Male	10	11.4	87.9	(42.1-161.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	29	29.5	98.2	(65.7-141)	Female	10	9	111.2	(53.2-204.5)
Female	19	28.8	65.9	(39.7-102.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	13	8.7	150.2	(79.9-256.8)
Male	2	7.2	nc	(nc-nc)	Female	11	8.8	125.1	(62.4-223.8)
Female	2	1.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	106	101	104.9	(85.9-126.9)
Male	0	1.7	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.4	nc	(nc-nc)	Male	3	6.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	2	3.5	nc	(nc-nc)
Male	9	13.9	64.7	(29.5-122.8)	<u>Testis</u>				
Female	7	7.9	88.5	(35.5-182.4)	Male	3	2.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	3.9	nc	(nc-nc)	Male	7	5.8	120.6	(48.3-248.4)
Female	0	1.2	nc	(nc-nc)	Female	17	17.6	96.4	(56.1-154.4)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	9.9	131.9	(70.1-225.5)	Female	16	23.3	68.7	(39.2-111.6)
Female	11	7	156.2	(77.9-279.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	342	352	97.2	(87.1-108)
Male	5	8.3	60.3	(19.4-140.7)	Female	372	337.5	110.2	(99.3-122)
Female	4	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	27	48	56.2	(37-81.8)					
Female	41	47.8	85.8	(61.6-116.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marion

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	7.7	nc	(nc-nc)	Male	7	4.7	149	(59.7-307.1)
Female	2	2.7	nc	(nc-nc)	Female	2	3.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.3	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	4.1	169.7	(68-349.6)
Female	36	27	133.6	(93.5-184.9)	Female	3	3.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	8.4	nc	(nc-nc)	Female	4	2.5	nc	(nc-nc)
Female	9	8.4	106.6	(48.6-202.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	2.5	nc	(nc-nc)
Male	2	2	nc	(nc-nc)	Female	3	2.6	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	33	27.9	118.3	(81.4-166.2)
Male	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1	nc	(nc-nc)
Male	0	3.8	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	5	4.4	114.7	(36.9-267.6)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	2.8	178.8	(57.6-417.2)	Female	5	6.3	79.2	(25.5-184.7)
Female	1	2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	85	99	85.9	(68.6-106.2)
Male	2	2.3	nc	(nc-nc)	Female	101	94	107.4	(87.5-130.5)
Female	1	0.8	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	6	13.9	43.2	(15.8-94.1)					
Female	14	13.9	100.8	(55.1-169.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	35.7	103.6	(72.9-142.8)	Male	16	24.6	65	(37.1-105.5)
Female	14	13.7	102.5	(56-171.9)	Female	14	20.5	68.3	(37.3-114.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.7	78	(28.5-169.8)	Male	7	6.6	106.2	(42.5-218.8)
Female	6	6.3	95	(34.7-206.8)	Female	6	5.5	109.1	(39.8-237.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	28	21.7	129.3	(85.9-186.9)
Female	130	147.9	87.9	(73.4-104.4)	Female	18	18.1	99.4	(58.9-157.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	5.7	140.8	(60.6-277.4)	Male	15	16.6	90.6	(50.7-149.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	41.9	93.1	(66.2-127.2)	Female	12	13.4	89.7	(46.3-156.6)
Female	53	43.7	121.2	(90.8-158.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	11.9	67.2	(28.9-132.4)
Male	13	9.8	132.3	(70.4-226.2)	Female	11	13.2	83.2	(41.5-148.9)
Female	5	2.7	182.3	(58.7-425.3)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	125	137	91.2	(75.9-108.7)
Male	5	3.5	141.7	(45.7-330.7)	<u>Stomach</u>				
Female	2	2.7	nc	(nc-nc)	Male	10	8.7	115	(55.1-211.5)
<u>Kidney & Renal Pelvis</u>					Female	4	5.4	nc	(nc-nc)
Male	32	20.4	157	(107.4-221.7)	<u>Testis</u>				
Female	8	11.7	68.3	(29.4-134.6)	Male	6	6.2	96.1	(35.1-209.3)
<u>Larynx</u>					<u>Thyroid</u>				
Male	4	5.4	nc	(nc-nc)	Male	8	9.7	82.5	(35.5-162.5)
Female	2	1.7	nc	(nc-nc)	Female	41	29.8	137.7	(98.8-186.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	17	14.5	116.8	(68-187.1)	Female	38	33.3	114.2	(80.8-156.8)
Female	12	11.1	107.7	(55.6-188.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	481	497.9	96.6	(88.2-105.6)
Male	12	11.7	102.3	(52.8-178.7)	Female	526	507.2	103.7	(95-113)
Female	7	4	174	(69.7-358.6)					
<u>Lung and Bronchus</u>									
Male	53	65.3	81.2	(60.8-106.2)					
Female	77	69.4	111	(87.6-138.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Marshfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	24.7	105.2	(68.7-154.1)	Male	41	17.3	237	(170-321.5)
Female	14	8.5	164.2	(89.7-275.5)	Female	28	13.8	203.5	(135.2-294.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.3	nc	(nc-nc)	Male	7	4.7	147.9	(59.2-304.7)
Female	6	4.3	140.7	(51.4-306.2)	Female	4	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.8	nc	(nc-nc)	Male	13	15	86.5	(46-147.9)
Female	140	105.7	132.5	(111.5-156.3)	Female	8	11.8	67.5	(29.1-133.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.9	127.4	(41-297.2)	Male	9	12.3	72.9	(33.3-138.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	33	29.5	112	(77.1-157.4)	Female	14	9.3	150.6	(82.2-252.6)
Female	29	27	107.5	(72-154.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	8.4	118.8	(56.9-218.5)
Male	6	7.3	82.4	(30.1-179.3)	Female	6	8.1	74.3	(27.1-161.8)
Female	2	1.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	122	105.9	115.2	(95.7-137.6)
Male	4	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	3	1.7	nc	(nc-nc)	Male	5	6.1	81.7	(26.3-190.6)
<u>Kidney & Renal Pelvis</u>					Female	4	3.2	nc	(nc-nc)
Male	23	14.9	154.5	(97.9-231.9)	<u>Testis</u>				
Female	6	8.1	74.1	(27.1-161.4)	Male	3	3.4	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.1	nc	(nc-nc)	Male	6	6.8	88.5	(32.3-192.7)
Female	2	1.2	nc	(nc-nc)	Female	28	20.7	135.5	(90-195.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	10	120	(61.9-209.6)	Female	28	24.7	113.3	(75.3-163.7)
Female	6	7	85.2	(31.1-185.5)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	411	360.1	114.1	(103.4-125.7)
Male	8	8.8	91	(39.2-179.3)	Female	437	343.6	127.2	(115.5-139.7)
Female	2	2.7	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	53	46.9	113	(84.6-147.8)					
Female	67	46.7	143.5	(111.2-182.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mashpee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	21.7	166	(116.2-229.8)	Male	21	13	161.4	(99.9-246.7)
Female	7	7.4	94.1	(37.7-194)	Female	15	9.6	155.7	(87.1-256.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.5	nc	(nc-nc)	Male	4	3.8	nc	(nc-nc)
Female	2	3	nc	(nc-nc)	Female	2	3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	15	11.4	131.7	(73.6-217.2)
Female	85	73.5	115.6	(92.3-142.9)	Female	12	9.4	127.7	(65.9-223.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.4	nc	(nc-nc)	Male	12	8.1	148.8	(76.8-260)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	23	82.7	(49.8-129.1)	Female	6	6.7	89.1	(32.5-193.9)
Female	28	22.5	124.5	(82.7-179.9)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	4	5.5	nc	(nc-nc)	Male	95	75.9	125.2	(101.3-153.1)
Female	0	1.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	1.3	nc	(nc-nc)	Male	5	1.8	281	(90.6-655.8)
Female	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	10.3	116.3	(60-203.2)	Female	16	17.3	92.4	(52.8-150)
Female	8	6.1	130.4	(56.1-256.9)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	4	3	nc	(nc-nc)	Male	9	7.7	116.4	(53.1-221)
Female	4	0.9	nc	(nc-nc)	Female	8	5.5	146.1	(62.9-287.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	3	6.1	nc	(nc-nc)	Male	34	39.3	86.5	(59.9-120.9)
Female	4	2.1	nc	(nc-nc)	Female	53	39.4	134.4	(100.6-175.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mattapoisett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.2	120.2	(59.9-215)	Male	8	5.8	138.7	(59.7-273.4)
Female	4	3.1	nc	(nc-nc)	Female	8	4.2	191.9	(82.6-378.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.6	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5	nc	(nc-nc)
Female	31	32.7	94.9	(64.5-134.7)	Female	3	4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.1	nc	(nc-nc)	Male	10	3.9	259	(124-476.4)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	10.2	59	(21.5-128.3)	Female	6	2.9	203.5	(74.3-442.9)
Female	16	9.5	169	(96.6-274.5)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3	nc	(nc-nc)
Male	1	2.5	nc	(nc-nc)	Female	2	2.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	45	35.4	127.1	(92.7-170.1)
Male	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.5	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.2	nc	(nc-nc)
Male	2	4.8	nc	(nc-nc)	<u>Testis</u>				
Female	0	2.6	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	6	5.5	109.4	(40-238.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	3.4	148.4	(47.8-346.4)	Female	8	7.7	103.5	(44.6-204)
Female	2	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	125	122.1	102.4	(85.2-122)
Male	2	2.8	nc	(nc-nc)	Female	112	111	100.9	(83.1-121.4)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	16.8	83.1	(45.4-139.4)					
Female	12	16.3	73.6	(38-128.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Maynard

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	10.2	107.9	(53.8-193.1)	Male	9	6.9	129.5	(59.1-245.9)
Female	0	3.9	nc	(nc-nc)	Female	9	5.9	152.6	(69.6-289.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	6.1	147.7	(67.4-280.4)
Female	45	43.8	102.8	(74.9-137.5)	Female	3	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.7	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	23	12	192.5	(122-288.8)	Female	2	3.9	nc	(nc-nc)
Female	17	12.4	137.5	(80.1-220.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.4	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	40	39.6	101	(72.1-137.5)
Male	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.5	nc	(nc-nc)
Male	4	5.8	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.4	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.6	nc	(nc-nc)	Male	4	2.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	11	8.6	127.4	(63.5-228)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.1	nc	(nc-nc)	Female	9	10	90.2	(41.2-171.3)
Female	3	3.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	144	141.8	101.5	(85.6-119.5)
Male	1	3.4	nc	(nc-nc)	Female	148	147.4	100.4	(84.9-118)
Female	4	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	11	18.7	58.8	(29.3-105.3)					
Female	21	20.3	103.7	(64.2-158.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	11.1	90.4	(43.3-166.2)	Male	14	7.8	178.6	(97.6-299.7)
Female	8	3.8	211.1	(90.9-415.9)	Female	10	6.2	162.2	(77.7-298.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.5	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
Female	4	2	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.9	nc	(nc-nc)
Female	58	47.9	121.1	(91.9-156.5)	Female	3	5.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	7	5.7	123.8	(49.6-255.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	13.5	140.9	(84.8-220.1)	Female	5	4.2	120.4	(38.8-280.9)
Female	18	12.4	145.5	(86.2-230)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	2	3.8	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	Female	1	3.6	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	54	46.1	117	(87.9-152.7)
Male	1	1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.8	nc	(nc-nc)	Male	1	2.8	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.5	nc	(nc-nc)
Male	4	6.8	nc	(nc-nc)	<u>Testis</u>				
Female	2	3.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.8	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	11	9.4	117.1	(58.4-209.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	4.6	nc	(nc-nc)	Female	11	10.8	102.2	(51-182.9)
Female	7	3.2	215.8	(86.5-444.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	158	161.2	98	(83.3-114.6)
Male	1	4	nc	(nc-nc)	Female	168	154.1	109	(93.1-126.8)
Female	2	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	12	20.8	57.7	(29.8-100.8)					
Female	13	20.2	64.4	(34.3-110.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	66	64.4	102.5	(79.3-130.4)	Male	29	40.4	71.8	(48.1-103.1)
Female	22	25.5	86.4	(54.1-130.8)	Female	25	34.3	73	(47.2-107.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	11	11.6	94.7	(47.2-169.4)	Male	5	11.2	44.6	(14.4-104)
Female	9	10.5	85.9	(39.2-163.1)	Female	11	10.1	109.2	(54.4-195.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2	nc	(nc-nc)	Male	29	35.8	81.1	(54.3-116.4)
Female	227	245.7	92.4	(80.7-105.2)	Female	23	32.2	71.3	(45.2-107.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.7	92	(39.6-181.3)	Male	34	25.3	134.5	(93.1-187.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	79	70.6	111.9	(88.6-139.5)	Female	23	22.8	100.7	(63.8-151.1)
Female	73	79.9	91.3	(71.6-114.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	14	16.4	85.4	(46.7-143.3)	Male	20	20.8	96.3	(58.8-148.7)
Female	5	5.2	96.7	(31.2-225.6)	Female	13	24.8	52.4	(27.9-89.6)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	7	5.2	134.5	(53.9-277.2)	Male	15	14.9	100.8	(56.4-166.2)
Female	4	4.5	nc	(nc-nc)	Female	10	9.9	100.7	(48.2-185.3)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	30	31.9	94.2	(63.5-134.5)	Male	10	8.8	113.5	(54.4-208.8)
Female	23	20.4	113	(71.6-169.6)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	8.9	146.5	(77.9-250.5)	Female	56	55.8	100.3	(75.8-130.3)
Female	1	3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	28	24.4	114.9	(76.4-166.1)	Male	759	826.2	91.9	(85.4-98.6)
Female	24	19.4	123.7	(79.2-184)	Female	822	878.3	93.6	(87.3-100.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	18	18.6	97	(57.5-153.4)	<u>All Sites / Types</u>				
Female	9	7.2	124.4	(56.8-236.2)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	109	114.7	95	(78-114.6)	<u>All Sites / Types</u>				
Female	122	128	95.3	(79.1-113.8)	<u>All Sites / Types</u>				

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Medway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	10.5	105.1	(52.4-188)	Male	7	7.6	92.6	(37.1-190.9)
Female	2	4	nc	(nc-nc)	Female	3	6.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.5	nc	(nc-nc)	Male	4	2	nc	(nc-nc)
Female	2	2	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	11	6.7	164.9	(82.2-295.1)
Female	42	48.3	86.9	(62.7-117.5)	Female	6	5.5	109.7	(40-238.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.9	nc	(nc-nc)	Male	3	5.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	19	12.8	148	(89-231.1)	Female	5	4.2	118.2	(38.1-275.9)
Female	16	13.1	122.3	(69.9-198.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.6	140.6	(45.3-328.2)
Male	7	3	230.4	(92.3-474.8)	Female	2	3.8	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	49	43	113.9	(84.2-150.5)
Male	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.8	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.6	nc	(nc-nc)
Male	4	6.5	nc	(nc-nc)	<u>Testis</u>				
Female	1	3.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.7	nc	(nc-nc)	Male	3	3.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	10	9.9	101.1	(48.4-185.9)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	4.5	nc	(nc-nc)	Female	5	10.6	47.1	(15.2-110)
Female	2	3.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	168	153.2	109.6	(93.7-127.5)
Male	3	3.8	nc	(nc-nc)	Female	141	158.2	89.1	(75-105.1)
Female	0	1.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	21	19.6	107.4	(66.4-164.1)					
Female	28	20.6	136	(90.3-196.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Melrose

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	31.6	98.3	(66.7-139.5)	Male	27	20.2	133.5	(87.9-194.2)
Female	18	12.6	142.3	(84.3-225)	Female	23	17.1	134.8	(85.4-202.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	5.9	204.9	(105.7-357.9)	Male	2	5.6	nc	(nc-nc)
Female	5	5.2	95.3	(30.7-222.3)	Female	3	5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1	nc	(nc-nc)	Male	21	17.8	117.9	(72.9-180.2)
Female	127	126.7	100.2	(83.5-119.2)	Female	15	16.1	93	(52-153.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	4.4	nc	(nc-nc)	Male	15	13.3	112.9	(63.1-186.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	39	35.6	109.6	(77.9-149.9)	Female	13	11.6	112	(59.6-191.6)
Female	47	40	117.6	(86.4-156.4)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	9	10.3	87.1	(39.7-165.3)
Male	9	8.4	107.8	(49.2-204.6)	Female	17	12.3	138.3	(80.5-221.4)
Female	3	2.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	103	115.1	89.5	(73.1-108.6)
Male	0	2.3	nc	(nc-nc)	<u>Stomach</u>				
Female	1	2	nc	(nc-nc)	Male	7	7.4	94	(37.7-193.6)
<u>Kidney & Renal Pelvis</u>					Female	5	4.9	101.2	(32.6-236.1)
Male	17	16.5	103.3	(60.1-165.4)	<u>Testis</u>				
Female	10	10.3	97.1	(46.5-178.5)	Male	1	3.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	8	4.5	175.8	(75.7-346.5)	Male	9	7.2	125.5	(57.3-238.2)
Female	2	1.5	nc	(nc-nc)	Female	28	22.7	123.2	(81.8-178)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	16	12.1	132.6	(75.7-215.3)	Female	28	28.8	97.3	(64.6-140.6)
Female	6	9.7	61.9	(22.6-134.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	415	417.1	99.5	(90.1-109.5)
Male	4	9.6	nc	(nc-nc)	Female	448	443.5	101	(91.9-110.8)
Female	3	3.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	56	56.9	98.4	(74.4-127.8)					
Female	54	63.7	84.7	(63.6-110.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mendon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.1	nc	(nc-nc)	Male	2	3.7	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	1	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	1	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	24	21.7	110.7	(70.9-164.7)	Female	6	2.3	256.7	(93.7-558.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.3	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
Female	5	5.4	92.9	(29.9-216.8)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	1	1.5	nc	(nc-nc)	Male	36	21.6	166.7	(116.8-230.8)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	3.2	nc	(nc-nc)	Female	4	4.8	nc	(nc-nc)
Female	4	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.8	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	3	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	1.9	nc	(nc-nc)	Male	7	9.6	73.3	(29.4-151)
Female	0	0.5	nc	(nc-nc)	Female	5	8.8	56.9	(18.3-132.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Merrimac

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	6.6	91.2	(33.3-198.5)	Male	4	4.4	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)	Female	7	3.5	200.8	(80.4-413.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	23	26.8	85.9	(54.5-129)	Female	4	3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	6	7.7	77.8	(28.4-169.4)	Female	4	2.3	nc	(nc-nc)
Female	7	7	100	(40.1-206.1)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	1.8	nc	(nc-nc)	Male	30	26.1	115.1	(77.7-164.4)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	1	0.6	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.7	nc	(nc-nc)	Female	7	6.1	114.7	(45.9-236.3)
Female	4	2	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	3	1	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	2	2.2	nc	(nc-nc)	Male	15	12.2	123.1	(68.9-203.1)
Female	2	0.7	nc	(nc-nc)	Female	18	11.9	151.4	(89.7-239.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Methuen

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	49.1	110	(82.6-143.5)	Male	23	31.7	72.5	(45.9-108.8)
Female	25	19.2	130	(84.1-192)	Female	27	26.8	100.8	(66.4-146.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	9	9.5	94.5	(43.1-179.3)	Male	10	8.8	114.1	(54.6-209.8)
Female	10	8.4	119.7	(57.3-220.2)	Female	4	7.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.5	nc	(nc-nc)	Male	24	28.1	85.3	(54.6-126.9)
Female	200	196.2	101.9	(88.3-117.1)	Female	24	24.8	96.8	(62-144.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	7.1	127.6	(58.2-242.3)	Male	17	20.8	81.8	(47.6-131)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	56	55.5	100.9	(76.2-131.1)	Female	10	17.9	55.8	(26.7-102.5)
Female	62	61	101.6	(77.9-130.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	21	16.1	130.7	(80.9-199.8)
Male	13	12.9	100.5	(53.5-171.9)	Female	17	18.7	91.1	(53-145.8)
Female	1	3.9	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	190	176.9	107.4	(92.7-123.8)
Male	4	4	nc	(nc-nc)	<u>Stomach</u>				
Female	2	3.4	nc	(nc-nc)	Male	13	11.6	112.2	(59.7-191.8)
<u>Kidney & Renal Pelvis</u>					Female	9	7.5	119.4	(54.5-226.6)
Male	22	25.7	85.5	(53.5-129.4)	<u>Testis</u>				
Female	15	15.9	94.5	(52.9-155.9)	Male	14	6.6	212.5	(116.1-356.6)
<u>Larynx</u>					<u>Thyroid</u>				
Male	7	7.1	99.2	(39.7-204.4)	Male	10	11.5	87.2	(41.7-160.3)
Female	3	2.3	nc	(nc-nc)	Female	36	36.6	98.3	(68.9-136.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	19	19.2	98.9	(59.5-154.5)	Female	44	44.2	99.5	(72.3-133.6)
Female	13	15.1	86	(45.7-147.1)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	659	650.5	101.3	(93.7-109.3)
Male	14	15.1	93	(50.8-156.1)	Female	705	684.7	103	(95.5-110.9)
Female	2	5.6	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	100	88.3	113.3	(92.2-137.8)					
Female	116	97.1	119.4	(98.7-143.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	22.6	141.7	(96.9-200.1)	Male	25	15.2	164.1	(106.1-242.2)
Female	15	8	186.6	(104.4-307.8)	Female	16	12.1	131.7	(75.3-214)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	4.7	128.9	(47.1-280.6)	Male	3	4.2	nc	(nc-nc)
Female	3	3.8	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	21	13.4	157.2	(97.2-240.2)
Female	102	90.1	113.3	(92.4-137.5)	Female	6	10.8	55.7	(20.4-121.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	3.3	149.6	(48.2-349.2)	Male	10	10.4	96.6	(46.2-177.6)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	40	26.2	152.8	(109.2-208.1)	Female	14	8.1	172.9	(94.5-290.2)
Female	31	25.4	121.8	(82.8-172.9)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	11	7.5	146.2	(72.9-261.5)
Male	10	6.3	159.1	(76.2-292.6)	Female	5	7.7	64.7	(20.9-151.1)
Female	2	1.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	108	88.9	121.5	(99.6-146.6)
Male	2	2	nc	(nc-nc)	<u>Stomach</u>				
Female	0	1.6	nc	(nc-nc)	Male	7	5.5	128.1	(51.3-263.9)
<u>Kidney & Renal Pelvis</u>					Female	0	3.1	nc	(nc-nc)
Male	18	12.7	141.4	(83.8-223.6)	<u>Testis</u>				
Female	2	7.1	nc	(nc-nc)	Male	8	3.2	249.2	(107.3-491)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	3.5	nc	(nc-nc)	Male	7	5.8	121.3	(48.6-249.9)
Female	2	1.1	nc	(nc-nc)	Female	20	17.6	113.9	(69.6-176)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	13	9	144.4	(76.8-247)	Female	29	20.7	140.3	(93.9-201.5)
Female	14	6.5	215	(117.5-360.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	403	314.1	128.3	(116.1-141.5)
Male	10	7.4	135.3	(64.8-248.8)	Female	372	304.1	122.3	(110.2-135.4)
Female	7	2.4	291	(116.6-599.6)					
<u>Lung and Bronchus</u>									
Male	40	41.7	95.9	(68.5-130.6)					
Female	63	42.1	149.5	(114.9-191.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middlefield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	0	2.9	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	5	9.7	51.6	(16.6-120.5)
Male	0	0.2	nc	(nc-nc)	Female	7	7.3	95.4	(38.2-196.5)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	1.3	nc	(nc-nc)					
Female	2	1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Middleton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.9	134.7	(69.5-235.3)	Male	7	6.3	110.2	(44.2-227.1)
Female	5	2.9	174.8	(56.3-408)	Female	6	4.3	139.4	(50.9-303.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	9	5.6	161	(73.4-305.6)
Female	33	33	99.9	(68.8-140.3)	Female	5	3.8	130.1	(41.9-303.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.2	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	7	10.6	65.9	(26.4-135.8)	Female	1	2.9	nc	(nc-nc)
Female	9	9	99.9	(45.6-189.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	6	3	201.3	(73.5-438.1)
Male	3	2.5	nc	(nc-nc)	Female	2	2.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	42	34.8	120.8	(87-163.3)
Male	0	1	nc	(nc-nc)	<u>Stomach</u>				
Female	2	0.5	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.1	nc	(nc-nc)
Male	3	5.3	nc	(nc-nc)	<u>Testis</u>				
Female	3	2.6	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	0.4	nc	(nc-nc)	Female	6	6.2	96.8	(35.3-210.7)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.7	nc	(nc-nc)	Female	3	7.6	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	144	127	113.4	(95.6-133.5)
Male	3	3	nc	(nc-nc)	Female	118	109.7	107.6	(89-128.8)
Female	1	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	14	16.4	85.2	(46.6-143)					
Female	19	15.4	123.4	(74.2-192.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	42	27.7	151.8	(109.4-205.3)	Male	11	18.7	59	(29.4-105.5)
Female	11	10.4	106	(52.9-189.7)	Female	13	15.3	84.9	(45.2-145.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	5.7	nc	(nc-nc)	Male	6	5.1	118.6	(43.3-258.2)
Female	1	4.7	nc	(nc-nc)	Female	7	4.2	167.9	(67.3-345.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	14	16.4	85.1	(46.5-142.8)
Female	86	111.1	77.4	(61.9-95.6)	Female	15	13.7	109.7	(61.4-180.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.2	nc	(nc-nc)	Male	12	12.5	95.8	(49.4-167.3)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	27	32.1	84.1	(55.4-122.4)	Female	7	10.1	69.3	(27.8-142.8)
Female	25	33.3	75	(48.5-110.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	10	9.2	109.1	(52.2-200.7)
Male	11	7.5	145.9	(72.7-261.1)	Female	6	10.1	59.7	(21.8-129.9)
Female	1	2.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	123	104.7	117.4	(97.6-140.1)
Male	6	2.5	236.4	(86.3-514.6)	<u>Stomach</u>				
Female	0	2	nc	(nc-nc)	Male	12	6.7	179.8	(92.8-314.1)
<u>Kidney & Renal Pelvis</u>					Female	1	4.1	nc	(nc-nc)
Male	15	15.4	97.5	(54.6-160.9)	<u>Testis</u>				
Female	5	8.8	56.7	(18.3-132.3)	Male	4	4.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	4.1	nc	(nc-nc)	Male	5	7.1	70.2	(22.6-163.9)
Female	1	1.3	nc	(nc-nc)	Female	20	21.9	91.4	(55.8-141.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	12	11.1	108	(55.7-188.6)	Female	21	25.1	83.8	(51.8-128.1)
Female	9	8.4	107	(48.8-203.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	397	380	104.5	(94.4-115.3)
Male	3	9	nc	(nc-nc)	Female	325	382.1	85.1	(76.1-94.8)
Female	1	3.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	50	50.3	99.4	(73.8-131)					
Female	57	52.4	108.7	(82.3-140.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	15.6	102.8	(58.7-167)	Male	4	10.1	nc	(nc-nc)
Female	11	5.9	185.9	(92.6-332.6)	Female	4	8.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3	169.5	(54.6-395.5)	Male	2	2.8	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	3	2.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	12	8.9	134.9	(69.6-235.7)
Female	50	60.6	82.6	(61.3-108.8)	Female	3	7.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.1	233.3	(75.2-544.4)	Male	8	6.7	119.2	(51.3-234.9)
<u>Colon / Rectum</u>					Female	3	3	nc	(nc-nc)
Male	14	17.6	79.5	(43.4-133.5)	<u>Ovary</u>				
Female	13	18.7	69.6	(37-119)	Female	8	5.5	144.4	(62.2-284.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.2	119.5	(38.5-279)	Male	4	5.1	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	11	5.7	191.7	(95.6-343.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	62	58.1	106.6	(81.7-136.7)
Female	1	1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.7	nc	(nc-nc)
Male	16	8.3	192.8	(110.1-313.1)	Female	4	2.3	nc	(nc-nc)
Female	8	4.9	163.1	(70.2-321.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	1.9	nc	(nc-nc)
Male	5	2.3	218.2	(70.3-509.3)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	11	11.1	99.5	(49.6-178.1)
Male	4	6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	4.6	153.3	(61.4-315.9)	Female	13	13.8	93.9	(49.9-160.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.9	nc	(nc-nc)	Male	228	208.7	109.3	(95.5-124.4)
Female	2	1.7	nc	(nc-nc)	Female	214	210.7	101.6	(88.4-116.1)
<u>Lung and Bronchus</u>									
Male	38	28.3	134.3	(95-184.3)					
Female	33	30.1	109.5	(75.3-153.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	7.3	178.6	(95-305.4)	Male	9	5.2	172.7	(78.8-327.8)
Female	2	2.5	nc	(nc-nc)	Female	8	4.2	189.4	(81.6-373.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	40	32.2	124.1	(88.7-169)	Female	4	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	6	3.7	160.4	(58.6-349.1)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	12	8.8	136	(70.2-237.6)	Female	2	2.8	nc	(nc-nc)
Female	11	8.1	136.4	(68-244)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	2	2.2	nc	(nc-nc)	Male	36	31.2	115.3	(80.8-159.7)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	4.5	155.1	(62.1-319.6)	Female	4	7.4	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	1.2	nc	(nc-nc)	Male	4	3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	5	2.1	234.3	(75.5-546.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	4	2.6	nc	(nc-nc)	Male	13	13.8	94.1	(50-160.9)
Female	0	0.8	nc	(nc-nc)	Female	12	13.8	86.9	(44.8-151.8)
<u>Male</u>					<u>Female</u>				
					Male	131	107.3	122.1	(102.1-144.9)
					Female	119	103.8	114.6	(94.9-137.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Millville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.1	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	6	10.1	59.5	(21.7-129.5)	Female	2	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	5	2.6	191.8	(61.8-447.7)	Female	0	0.9	nc	(nc-nc)
Female	1	2.6	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	8.9	112.9	(54.1-207.7)
Male	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.3	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.9	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	31	31.6	98	(66.6-139.1)
Male	1	0.8	nc	(nc-nc)	Female	29	32.9	88.2	(59.1-126.7)
Female	1	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	3.9	nc	(nc-nc)					
Female	9	4.2	213.9	(97.6-406.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Milton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	30.6	85.1	(55.6-124.7)	Male	35	19.3	181.6	(126.5-252.6)
Female	4	12.1	nc	(nc-nc)	Female	24	16.2	148	(94.8-220.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.7	88	(28.4-205.4)	Male	8	5.4	147.5	(63.5-290.7)
Female	5	5.1	98.7	(31.8-230.4)	Female	6	4.8	124.2	(45.4-270.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1	nc	(nc-nc)	Male	10	17.2	58.3	(27.9-107.1)
Female	112	121.5	92.2	(75.9-110.9)	Female	15	15.4	97.2	(54.4-160.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.1	nc	(nc-nc)	Male	8	12.7	63.2	(27.2-124.5)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	28	34.3	81.6	(54.2-118)	Female	17	11.1	152.9	(89-244.9)
Female	44	38.6	114.1	(82.9-153.2)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	8	9.9	80.4	(34.6-158.5)
Male	5	8	62.6	(20.2-146.2)	Female	10	11.8	84.6	(40.5-155.7)
Female	5	2.4	204.2	(65.8-476.6)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	126	108.9	115.7	(96.4-137.8)
Male	0	2.2	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2	nc	(nc-nc)	Male	0	7.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	3	4.8	nc	(nc-nc)
Male	16	15.6	102.4	(58.5-166.3)	<u>Testis</u>				
Female	10	9.8	101.6	(48.6-186.9)	Male	6	3.4	178.1	(65-387.7)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	4.3	nc	(nc-nc)	Male	11	6.7	164.4	(82-294.2)
Female	1	1.4	nc	(nc-nc)	Female	32	21.3	150.2	(102.8-212.1)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	15	11.8	127.3	(71.2-210)	Female	34	27.3	124.3	(86.1-173.7)
Female	9	9.4	96.2	(43.9-182.6)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	376	399.2	94.2	(84.9-104.2)
Male	4	9.3	nc	(nc-nc)	Female	426	424.4	100.4	(91.1-110.4)
Female	3	3.5	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	37	54.6	67.8	(47.7-93.4)					
Female	52	60.7	85.6	(63.9-112.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monroe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
					Female	0	0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0	nc	(nc-nc)	Male	0	0	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0	nc	(nc-nc)	Male	3	0.5	nc	(nc-nc)
Female	0	0	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0	nc	(nc-nc)	Male	0	0	nc	(nc-nc)
Female	0	0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0	nc	(nc-nc)	Male	0	0	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	1.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monson

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	8.7	80.4	(32.2-165.7)	Male	8	6.1	130.7	(56.3-257.6)
Female	4	3	nc	(nc-nc)	Female	1	4.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	1.9	266.9	(86-622.8)	Male	0	1.7	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.3	93.8	(30.2-218.8)
Female	38	36.2	104.9	(74.2-144)	Female	1	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.3	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	10	10.4	95.7	(45.8-176.1)	Female	2	3.2	nc	(nc-nc)
Female	9	9.7	92.5	(42.2-175.6)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3	169.1	(54.5-394.7)
Male	2	2.6	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	39	36.8	106.1	(75.4-145)
Male	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.6	nc	(nc-nc)	Male	4	2.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	4	5.2	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.8	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	1.4	nc	(nc-nc)	Male	0	2.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	7.1	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	6	3.5	171	(62.4-372.2)	Female	8	8.3	95.9	(41.3-188.9)
Female	2	2.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	126	126.4	99.6	(83-118.6)
Male	5	3.1	160.9	(51.8-375.4)	Female	100	119.3	83.8	(68.2-101.9)
Female	0	0.9	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	13	16.4	79.3	(42.2-135.6)					
Female	15	16.1	93	(52-153.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montague

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.2	78.7	(33.9-155)	Male	6	6.6	91.5	(33.4-199.2)
Female	6	3.8	156	(56.9-339.4)	Female	2	5.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	1.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	5.8	nc	(nc-nc)
Female	40	38.9	102.8	(73.4-139.9)	Female	3	4.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	0	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	16	11.4	140.1	(80-227.5)	Female	4	3.6	nc	(nc-nc)
Female	10	12	83	(39.7-152.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	3	3.3	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	Female	4	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	30	37.7	79.6	(53.7-113.7)
Male	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.4	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	1.5	nc	(nc-nc)
Male	6	5.3	112.5	(41.1-244.9)	<u>Testis</u>				
Female	2	3.2	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	1.5	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	2	7	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	4	3.9	nc	(nc-nc)	Female	11	9	122	(60.8-218.2)
Female	1	2.9	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	119	135.4	87.9	(72.8-105.1)
Male	1	3.2	nc	(nc-nc)	Female	116	136.1	85.3	(70.4-102.3)
Female	0	1.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	18	18.5	97.4	(57.7-154)					
Female	21	19.8	106.3	(65.8-162.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Monterey

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.6	nc	(nc-nc)	Male	2	1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	5.2	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.8	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.2	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	21.6	50.9	(25.4-91)
Female	0	0.3	nc	(nc-nc)	Female	7	17.2	40.8	(16.3-84)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	0	0.5	nc	(nc-nc)					
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	3	nc	(nc-nc)					
Female	1	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Montgomery

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.9	nc	(nc-nc)	Male	2	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	5	4.2	119.6	(38.5-279)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	2	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	2	1.8	nc	(nc-nc)	Male	12	13.9	86.1	(44.4-150.4)
Female	3	1.5	nc	(nc-nc)	Female	9	11.2	80.2	(36.6-152.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Mount Washington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
					Female	0	0	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)					
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)					
<u>Kidney & Renal Pelvis</u>					<u>Stomach</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0	nc	(nc-nc)	Male	0	0	nc	(nc-nc)
Female	0	0	nc	(nc-nc)					
<u>Leukemia</u>					<u>Thyroid</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)					
<u>Lung and Bronchus</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	2	4	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nahant

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.9	84.5	(27.2-197.2)	Male	9	3.6	251.1	(114.6-476.7)
Female	3	1.9	nc	(nc-nc)	Female	1	2.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	1	1	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	3.1	158.8	(51.2-370.5)
Female	21	19.6	107.4	(66.5-164.2)	Female	0	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	4	6.5	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
Female	7	6.1	114.6	(45.9-236.1)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	2	1.5	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	18	21.1	85.2	(50.4-134.6)
Female	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	2.9	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	2	0.8	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	4	2.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)	Female	3	3.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	2	1.7	nc	(nc-nc)	Female	4	4.5	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	8	10.6	75.6	(32.6-149)	Male	71	75.5	94	(73.4-118.6)
Female	4	9.8	nc	(nc-nc)	Female	64	67.5	94.8	(73-121)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Nantucket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	9.4	106.7	(51.1-196.2)	Male	25	6.7	373.1	(241.4-550.8)
Female	4	3.2	nc	(nc-nc)	Female	17	5.2	326.8	(190.3-523.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.1	nc	(nc-nc)	Male	4	1.8	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.8	85.8	(27.7-200.3)
Female	51	37.3	136.7	(101.8-179.7)	Female	3	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	6	4.5	132.8	(48.5-289)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	13	11.1	117	(62.2-200)	Female	5	3.3	150.1	(48.4-350.3)
Female	12	10.3	116.8	(60.3-204)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	5	3.2	158.6	(51.1-370.1)
Male	2	2.7	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
Female	5	0.7	764.4	(246.3-1783.8)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	68	37.7	180.3	(140-228.5)
Male	4	1	nc	(nc-nc)	<u>Stomach</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	1	1.2	nc	(nc-nc)
Male	2	5.6	nc	(nc-nc)	<u>Testis</u>				
Female	1	2.9	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	1	1.5	nc	(nc-nc)	Male	5	2.7	182.5	(58.8-425.8)
Female	0	0.4	nc	(nc-nc)	Female	5	8	62.8	(20.2-146.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	8	3.8	208.2	(89.6-410.2)	Female	9	8.4	106.7	(48.7-202.6)
Female	2	2.7	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	195	134.7	144.8	(125.2-166.6)
Male	0	3.2	nc	(nc-nc)	Female	149	125.6	118.6	(100.3-139.3)
Female	0	1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	16	17.5	91.3	(52.2-148.3)					
Female	13	17	76.4	(40.6-130.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Natick

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	35.4	112.9	(80.6-153.7)	Male	25	23.3	107.3	(69.4-158.4)
Female	17	13.5	126.2	(73.5-202.1)	Female	17	19.5	87.4	(50.9-139.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	7	230	(131.4-373.6)	Male	8	6.4	124.5	(53.6-245.4)
Female	9	6	150.6	(68.7-285.9)	Female	6	5.4	110.4	(40.3-240.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.1	nc	(nc-nc)	Male	17	20.5	83.1	(48.4-133)
Female	165	144.4	114.3	(97.5-133.1)	Female	16	17.6	90.7	(51.8-147.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	5.3	nc	(nc-nc)	Male	15	15.5	96.9	(54.2-159.9)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	52	40.4	128.8	(96.2-168.9)	Female	14	13	107.5	(58.7-180.5)
Female	38	42.6	89.1	(63.1-122.3)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	14	11.7	119.8	(65.4-201)
Male	7	9.6	73.3	(29.4-151)	Female	12	13	92.3	(47.6-161.2)
Female	3	2.7	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	131	132.6	98.8	(82.6-117.3)
Male	1	2.8	nc	(nc-nc)	<u>Stomach</u>				
Female	3	2.4	nc	(nc-nc)	Male	12	8.4	142.2	(73.4-248.3)
<u>Kidney & Renal Pelvis</u>					Female	3	5.2	nc	(nc-nc)
Male	18	19.2	93.9	(55.6-148.4)	<u>Testis</u>				
Female	11	11.5	95.4	(47.6-170.7)	Male	1	4.6	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	3	5.2	nc	(nc-nc)	Male	17	8.5	199.1	(115.9-318.7)
Female	3	1.7	nc	(nc-nc)	Female	24	27.4	87.7	(56.2-130.5)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	11	13.8	79.5	(39.6-142.2)	Female	28	32.8	85.4	(56.7-123.4)
Female	12	10.6	112.7	(58.2-196.8)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	499	478.1	104.4	(95.4-113.9)
Male	4	11.2	nc	(nc-nc)	Female	505	494.1	102.2	(93.5-111.5)
Female	2	4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	55	64.6	85.2	(64.2-110.9)					
Female	67	69.5	96.4	(74.7-122.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Needham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	40	36.8	108.6	(77.6-147.9)	Male	34	22.7	149.6	(103.6-209)
Female	11	14.2	77.2	(38.5-138.1)	Female	23	18.2	126.6	(80.2-189.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	6.5	76.5	(24.6-178.4)	Male	8	6.5	124	(53.4-244.4)
Female	8	5.7	140.9	(60.7-277.7)	Female	2	5.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.1	nc	(nc-nc)	Male	29	20.3	143.1	(95.8-205.6)
Female	156	137.3	113.6	(96.5-132.9)	Female	18	17.8	101.3	(60-160)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.6	nc	(nc-nc)	Male	13	14.8	87.8	(46.7-150.2)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	35	41	85.4	(59.4-118.7)	Female	12	12.7	94.8	(49-165.7)
Female	32	45.5	70.4	(48.1-99.3)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	5	9.5	52.8	(17-123.2)	Male	11	11.9	92.1	(45.9-164.9)
Female	4	2.8	nc	(nc-nc)	Female	18	13.9	129.1	(76.5-204)
<u>Hodgkin Lymphoma</u>					<u>Stomach</u>				
Male	2	2.4	nc	(nc-nc)	Male	7	8.6	81.6	(32.7-168.2)
Female	1	2	nc	(nc-nc)	Female	2	5.7	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					<u>Testis</u>				
Male	11	18.3	60	(29.9-107.3)	Male	5	3.4	145.5	(46.9-339.6)
Female	9	11.2	80.5	(36.7-152.8)	<u>Thyroid</u>				
<u>Larynx</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	5	5.1	97.7	(31.5-227.9)	Female	30	30.8	97.3	(65.7-139)
Female	1	1.6	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	7	14	50.1	(20.1-103.3)	Male	455	472.1	96.4	(87.7-105.7)
Female	14	10.9	128.7	(70.3-216)	Female	469	484.2	96.9	(88.3-106)
<u>Liver and Intrahepatic Bile Ducts</u>									
Male	5	10.8	46.2	(14.9-107.7)					
Female	1	4	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	38	65.3	58.2	(41.2-79.9)					
Female	44	69.2	63.6	(46.2-85.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Ashford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male				
Male	0	0.1	nc	(nc-nc)	Male	1	0.1	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male				
Male	0	0.2	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0	nc	(nc-nc)
<u>Larynx</u>					<u>Testis</u>				
Male	0	0	nc	(nc-nc)	Male	0	0	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>Thyroid</u>				
<u>Leukemia</u>					Male				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Lung and Bronchus</u>					Male				
Male	0	0.5	nc	(nc-nc)	Male	5	4	124.8	(40.2-291.3)
Female	0	0.5	nc	(nc-nc)	Female	4	3.6	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	112	101.1	110.8	(91.2-133.3)	Male	37	64.2	57.7	(40.6-79.5)
Female	40	41.2	97	(69.3-132.1)	Female	23	55.4	41.5	(26.3-62.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	17	19.2	88.4	(51.4-141.5)	Male	18	17.7	101.4	(60.1-160.3)
Female	23	17.4	131.8	(83.5-197.8)	Female	15	16.3	92.2	(51.5-152)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	3.1	nc	(nc-nc)	Male	48	57	84.2	(62.1-111.6)
Female	334	396.4	84.3	(75.5-93.8)	Female	39	52.2	74.7	(53.1-102.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	29	14	206.8	(138.5-297)	Male	56	40.9	137.1	(103.5-178)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	106	112	94.6	(77.5-114.4)	Female	27	36.9	73.1	(48.2-106.4)
Female	106	129.9	81.6	(66.8-98.7)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	34	32.8	103.6	(71.8-144.8)
Male	41	26.1	157	(112.7-213)	Female	56	40.2	139.2	(105.1-180.7)
Female	8	8.3	96	(41.3-189.1)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	428	355.1	120.5	(109.4-132.5)
Male	9	8.4	106.6	(48.7-202.4)	<u>Stomach</u>				
Female	5	7.3	68.3	(22-159.3)	Male	34	23.6	144.2	(99.9-201.6)
<u>Kidney & Renal Pelvis</u>					Female	25	16.2	154.7	(100.1-228.4)
Male	72	51.2	140.6	(110-177.1)	<u>Testis</u>				
Female	43	32.9	130.8	(94.7-176.2)	Male	9	14.1	63.9	(29.1-121.2)
<u>Larynx</u>					<u>Thyroid</u>				
Male	16	14.2	112.9	(64.5-183.4)	Male	20	22.7	88.2	(53.9-136.2)
Female	15	4.7	316.7	(177.1-522.4)	Female	65	73.2	88.8	(68.5-113.2)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	42	39.3	106.8	(76.9-144.3)	Female	97	89.8	108	(87.6-131.8)
Female	23	32.2	71.5	(45.3-107.2)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	1505	1317.1	114.3	(108.6-120.2)
Male	60	29.8	201.4	(153.7-259.2)	Female	1337	1420.2	94.1	(89.2-99.3)
Female	14	11.7	119.7	(65.4-200.9)					
<u>Lung and Bronchus</u>									
Male	241	180.8	133.3	(117-151.2)					
Female	184	205.4	89.6	(77.1-103.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	1	4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	2	4	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.1	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.4	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	7	13.9	50.3	(20.1-103.6)
Male	1	0.4	nc	(nc-nc)	Female	8	13.2	60.6	(26.1-119.5)
Female	0	0.1	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	0	1.7	nc	(nc-nc)					
Female	0	1.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Marlborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	3	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	7	7.2	97.9	(39.2-201.7)	Female	1	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	3	2.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	1	2	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					Male	0	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Prostate</u>				
<u>Hodgkin Lymphoma</u>					Male	10	9.2	109.1	(52.2-200.7)
Male	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Kidney & Renal Pelvis</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	<u>Testis</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Larynx</u>					<u>Thyroid</u>				
Male	2	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Leukemia</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	0	0.8	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Liver and Intrahepatic Bile Ducts</u>					Male	24	31	77.3	(49.5-115)
Male	0	0.7	nc	(nc-nc)	Female	18	24.2	74.4	(44.1-117.6)
Female	0	0.2	nc	(nc-nc)					
<u>Lung and Bronchus</u>									
Male	1	4.3	nc	(nc-nc)					
Female	1	3.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

New Salem

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	3	4.3	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					<u>Ovary</u>				
Male	1	1.4	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	1	nc	(nc-nc)	<u>Pancreas</u>				
<u>Esophagus</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	5	5.2	95.4	(30.7-222.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Hodgkin Lymphoma</u>					<u>Testis</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
<u>Kidney & Renal Pelvis</u>					<u>Uteri Corpus and Uterus, NOS</u>				
Male	1	0.7	nc	(nc-nc)	Female	4	1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	<u>All Sites / Types</u>				
<u>Larynx</u>					<u>Leukemia</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>Lung and Bronchus</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;